Financial giants have made a conspicuous bullish move on Iovance Biotherapeutics. Our analysis of options history for Iovance Biotherapeutics IOVA revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $62,000, and 6 were calls, valued at $197,120.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $10.5 for Iovance Biotherapeutics during the past quarter.
Insights into Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Iovance Biotherapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Iovance Biotherapeutics's whale activity within a strike price range from $9.0 to $10.5 in the last 30 days.
Iovance Biotherapeutics Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | CALL | SWEEP | BULLISH | 11/15/24 | $1.3 | $1.05 | $1.3 | $10.00 | $38.5K | 3.2K | 300 |
| IOVA | CALL | TRADE | BULLISH | 10/25/24 | $0.55 | $0.45 | $0.55 | $10.00 | $38.5K | 6.4K | 1.8K |
| IOVA | PUT | SWEEP | BEARISH | 01/17/25 | $1.1 | $0.85 | $1.1 | $9.00 | $33.0K | 5.8K | 300 |
| IOVA | CALL | SWEEP | BULLISH | 12/20/24 | $1.65 | $1.5 | $1.65 | $10.00 | $33.0K | 1.8K | 200 |
| IOVA | CALL | SWEEP | NEUTRAL | 10/25/24 | $0.25 | $0.2 | $0.25 | $10.50 | $32.3K | 2.7K | 1.3K |
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Having examined the options trading patterns of Iovance Biotherapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Iovance Biotherapeutics
- Trading volume stands at 1,728,335, with IOVA's price up by 7.03%, positioned at $10.51.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 12 days.
Expert Opinions on Iovance Biotherapeutics
1 market experts have recently issued ratings for this stock, with a consensus target price of $17.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * In a cautious move, an analyst from UBS downgraded its rating to Buy, setting a price target of $17.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iovance Biotherapeutics with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
